Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Lenvatinib |
Trade Name | Lenvima |
Synonyms | E7080 |
Drug Descriptions |
Lenvima (lenvatinib) inhibits VEGFR, FGFR, PDGFR, KIT, and RET, and suppresses cell proliferation and angiogenesis (PMID: 21781317, PMID: 25295214, PMID: 17943726). Lenvima (lenvatinib) is FDA approved for use in patients with radioactive iodine-refractory differentiated thyroid cancer, unresectable hepatocellular carcinoma, in combination with Keytruda (pembrolizumab) as first line, or with Afinitor (everolimus) for renal cell carcinoma, and in combination with Pembrolizumab for endometrial carcinoma that is not MSI-H or dMMR (FDA.gov). |
DrugClasses | FGFR Inhibitor (Pan) 24 KIT Inhibitor 55 PDGFR Inhibitor (Pan) 28 RET Inhibitor 48 VEGFR Inhibitor (Pan) 33 |
CAS Registry Number | 417716-92-8 |
NCIT ID | C95124 |